Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Humira opvejer risiciene til behandling af reumatoid arthritis, polyartikulær juvenil idiopatisk artritis, psoriasisgigt, ankylosing spondylitis, Crohns sygdom og psoriasis.
The Committee for Medicinal Products for Human Use (CHMP) decided that Humira’ s benefits are greater than its risks for treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’ s disease and psoriasis.